Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Boule Diagnostics ABBDABF 47 5-Year Yield-on-Cost % is 0.00 as of Jul. 14, 2026. GuruFocus rates BDABF with a GF Score™ of 47/100 and a GF Value™ of $14.73. The stock has 2 warning signs investors should review. Among 327 Medical Devices & Instruments companies, Boule Diagnostics AB ranks worse than 305810.09% on this metric.
Boule Diagnostics AB's yield on cost for the quarter that ended in Mar. 2026 was 0.00.
The historical rank and industry rank for Boule Diagnostics AB's 5-Year Yield-on-Cost % or its related term are showing as below:
During the past 13 years, Boule Diagnostics AB's highest Yield on Cost was 3.92. The lowest was 0.17. And the median was 0.91.
BDABF's 5-Year Yield-on-Cost % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.33 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Boule Diagnostics AB (OTCPK:BDABF) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Boule Diagnostics AB 5-Year Yield-on-Cost % Related Terms
BDABF vs ABT, SYK, MDT: 5-Year Yield-on-Cost % Comparison
For the Medical Devices subindustry, Boule Diagnostics AB's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Boule Diagnostics AB 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Boule Diagnostics AB's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Boule Diagnostics AB's 5-Year Yield-on-Cost % falls into.
Boule Diagnostics AB 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Boule Diagnostics AB (BDABF) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 14, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Boule Diagnostics AB and its competitors. Over the past decade, Boule Diagnostics AB's 5-Year Yield-on-Cost % has ranged from 0.17 to 3.92. According to the industry distribution chart, Boule Diagnostics AB ranks #999999 out of 327 companies in the Medical Devices & Instruments industry.
Is Boule Diagnostics AB's 5-Year Yield-on-Cost % too high?
Boule Diagnostics AB's current 5-Year Yield-on-Cost % is 0.00. Over the past 10 years, this metric has ranged from a low of 0.17 to a high of 3.92. Based on the distribution chart, Boule Diagnostics AB ranks #999999 out of 327 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Boule Diagnostics AB has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Boule Diagnostics AB's 5-Year Yield-on-Cost % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Boule Diagnostics AB ranks #999999 out of 327 companies for 5-Year Yield-on-Cost %. This places Boule Diagnostics AB in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.33. Historically, Boule Diagnostics AB's own 5-Year Yield-on-Cost % has ranged from 0.17 to 3.92 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.33, based on 327 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Boule Diagnostics AB and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Boule Diagnostics AB's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boule Diagnostics AB stock overvalued right now?
Boule Diagnostics AB (BDABF) has a current 5-Year Yield-on-Cost % of 0.00. The stock's GF Value™ is $14.73, compared to a current price of $7.84 — trading 46.8% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Boule Diagnostics AB's overall GF Score™ is 47/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Boule Diagnostics AB (BDABF), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Boule Diagnostics AB (BDABF) Overvalued in 2026?
Based on GuruFocus' analysis, Boule Diagnostics AB stock appears to be undervalued.
The current stock price of $7.84 is trading 46.8% below its estimated GF Value™ of $14.73.
Key valuation signals for BDABF:
5-Year Yield-on-Cost %: 0.00
GF Value™: $14.73 vs. price of $7.84 (46.8% below fair value)
No single metric tells the full story. See the BDABF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Boule Diagnostics AB is a company operating in the diagnostics market. It is engaged in the development, manufacturing and marketing instruments and consumables for blood diagnostics. The systems are intended for small and medium-sized hospitals, clinics and laboratories within outpatient care. the company operating through two complementary business segments: Diagnostics and OEM CDS. Through its subsidiaries, the company operates in USA ,Asia, Eastern Europe, Latin America Western Europe and Africa / Middle East. The majority revenue is generated from Asia.
47GF Score
Get the complete analysis for BDABF
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BDABF has been successfully added to your 
